A novel cutting-edge technology is accelerating the development of next-generation cancer treatments, with AIBN now home to an AdvanCell Lead-212 generator.
The long-standing partnership between AIBN and Clarity Pharmaceuticals continues to thrive with the signing of a brand-new Supply Agreement for radionuclide, Copper-64.
Molecular radiotherapy (MRT) involves targeted delivery of ionising radiation to trigger localised cell death. Targeted irradiation is achieved using alpha (α) or beta (β-) emitting radionuclides that are incorporated into a radiopharmaceutical.
AIBN researcher Dr Nick Fletcher has won an Advance Queensland Industry Research Fellowship to explore localised cell death and the immune response to cancer.
Despite the remarkable ability of nanomedicines to diagnose and treat disease, activation of the immune system and the development of innate and adaptive immunity against specific subsets of nanomedicines is a significant unresolved challenge.
Targeted alpha-therapies (TATs) are emerging as powerful radiopharmaceutical tools for cancer treatment, allowing precise and localised dosing of highly potent radiotherapy.
